Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/10/2008

ulation, entry criteria and study conduct. OncoGenex plans to

revise and submit the protocol to FDA for a Special Protocol

Assessment prior to initiating the registration trial.

- OncoGenex completed patient enrollment in its Phase 1 clinical trial

evaluating the safety of SN2310 in patients with advanced cancer.

Conference Call on Monday, November 10, 2008 at 4:30 p.m. Eastern Time

OncoGenex management will host a conference call on Monday, November 10, 2008, at 4:30 p.m. Eastern Time to provide a business and product update and discuss the third quarter results. To access the webcast, log on to the Investor Relations page of the OncoGenex Web site at http://www.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-548-7903 (U.S. & Canada) or 719-325-4917 (International). A webcast replay will be available approximately two hours after the call and will be archived on http://www.oncogenex.com for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed enrollment in a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at http://www.oncogenex.com
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market ... their offering. The global companion diagnostics ... 22.7% from 2014 to 2019. Factors such as rising ... of companion diagnostics by the pharmaceutical industry, support from ...
(Date:9/18/2014)... 18, 2014  U.S. biotech company Kultevat ... license for technology developed by the Donald Danforth ... plants, including for applications in production of natural rubber ... technology was developed under the direction of Roger ... former president of the Danforth Plant Science Center, and ...
(Date:9/18/2014)... 18, 2014  Neogen Corporation (Nasdaq: NEOG ... strategic agreement with Merck Animal Health to market Neogen,s ... The Igenity Dairy Heifer Program consists of genomic tests ... genetic potential of replacement dairy heifers. The genomic tests ... and is an excellent tool in the decision-making process ...
(Date:9/18/2014)... 18 septembre 2014 Mapi, société créée ... 1974, a été depuis 40 ans l,un ... cliniques traditionnelles par des évaluations recentrées sur ... les impacts économiques des traitements. ... A cours d,une récente conférence téléphonique ...
Breaking Biology Technology:Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Kultevat obtains license of gene switch technology 2Merck Animal Health to market Neogen's dairy genomic program 21974 - 2014 - Mapi fĂȘte ses 40 ans 2
... Scimitar Equity, LLC issues a review ... entitled, "510k,Application Submitted for Xyfid(TM) and Priority ... Price Appreciation.", This review is available ... Pharmaceuticals is a New Jersey-based biotechnology company,dedicated ...
... 29 Zenobia Therapeutics, Inc.,(Zenobia) announced today ... award from The Michael J. Fox Foundation ... with potential to,fundamentally alter the course of ... Christopher Ross of Johns Hopkins University,Zenobia will ...
... July 29 ArunA Biomedical, Inc., the first,company ... and,services, announced today that William T. Sharp has ... to his ArunA leadership,responsibilities, Mr. Sharp has also ... succeeds ArunA founder Steven Stice, PhD, who will,remain ...
Cached Biology Technology:VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC 2Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2 2ArunA Biomedical Names William T. Sharp President and Chief Executive Officer 2
(Date:9/18/2014)... researchers from McGill University and the Quebec government ... ,microbeads, Canadian Journal of Fisheries and Aquatic ... cosmetics, household cleansers, or industrial cleansers, to which ... their small size and buoyancy, they may readily ... a global contaminant in the world,s oceans, but ...
(Date:9/18/2014)... creatively manipulate spoken language is unique to humans. "The ... years of human evolution to make this possible are ... we now have," says Wolfgang Enard, Professor of Anthropology ... understand the molecular biological basis of language Enard has ... his latest study, undertaken in collaboration with scientists at ...
(Date:9/18/2014)... and ethnic groups describe losing eyesight as potentially ... more so than other conditions including: loss of ... 49% of non-Hispanic whites, 43% of Asians and ... ailment is the worst that could happen to ... AIDS/HIV. Hispanics and Asians ranked cancer first ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... not the size of the eyespots on a male ... Instead, females are attracted to the "sparkle" created by ... at the center of eyespots, according to new research ... be published online June 29 in the Proceedings of ...
... between the two viruses could one day lead to ... researcher has discovered an unexpected link between the viruses ... an experimental strain of the human AIDS virus appear ... version of the disease as those immunized with the ...
... in a single gene can result in two ... to frequent or unusually severe infections, according to ... Nature Genetics. The discovery may lead to new ... A (IgA) deficiency and common variable immunodeficiency (CVID). ...
Cached Biology News:Female butterflies go for sparkle -- not size -- when choosing to mate 2Female butterflies go for sparkle -- not size -- when choosing to mate 3UF scientist finds unexpected link between cat and human AIDS viruses 2Agreement will speed research on microbicides for women 2Agreement will speed research on microbicides for women 3
Request Info...
R26.4C...
... x H): 17 3/4" x 8 ... slidesTime: Programmable 0 - 100 hoursControl: Programmable ... steps 40 user programmable protocols 3 operating ... Rapid temperature ramp-up from 37 - 95C ...
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Biology Products: